Inactive Instrument
CARDIUM THRPTCS Stock NYSE
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
NYSE
|
||
| - USD | - |
|
| 30/03/22 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| 04/09/21 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 22/12/2003 | |
James Grainer
DFI | Director of Finance/CFO | 71 | 22/05/2020 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 73 | 22/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
James Grainer
CHM | Chairman | 71 | 22/05/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -11.83% | -12.10% | +7.65% | +58.42% | 58.7B | |
| -1.44% | +1.57% | +4.52% | +32.73% | 48.36B | |
| +0.50% | -2.14% | +331.33% | +702.20% | 43.05B | |
| -0.72% | -3.99% | +28.50% | +29.94% | 42.48B | |
| +0.34% | -0.52% | +6.56% | +109.35% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -0.50% | -3.10% | -10.19% | -14.35% | 23.93B | |
| -3.32% | -10.86% | -37.32% | +316.28% | 22.22B | |
| Average | -1.43% | -2.18% | +43.29% | +153.49% | 42.9B | |
| Weighted average by Cap. | -1.38% | -1.56% | +50.03% | +146.09% |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
